Delivery systems for immunomodulatory proteins and peptides

BioDrugs

Volumn 7, Issue 1, 1997, Pages 51-65

  Anderson, Peter M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CYCLOSPORIN; CYTOKINE; DRUG CARRIER; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLIPOSOME; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; LIPOSOME; MICROSPHERE; MURAMYL TRIPEPTIDE; PEPTIDES AND PROTEINS; POLYMER; POLYPEPTIDE; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VIRUS VACCINE;

AEROSOL; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG TARGETING; ENCAPSULATION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW;

EID: 0030758668     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707010-00007     Document Type: Review

References (90)

1. Weiner AL. Liposomes for protein delivery: selecting manufacture and development processes. Immunomethods 1994; 4: 201-9
2. Shahum E, Thérien HM. Correlation between in vitro and in vivo behavior of liposomal antigens. Vaccine 1994; 12 (12): 1125-31
3. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991; 140: 1-13
4. Bergers JJ, ten Hagen TLM, van Etten EWM, et al. Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm World Sci 1995; 17: 1-11
5. Tan L, Gregoriadis G. A novel positively-charged lipid 1,2-bis-(hexadecylcycloxy)-3-trimethyl aminopropane (BisHOP) enhances the adjuvant effect of liposomes on encapsulated tetanus toxoid. Asian Pac J Allergy Immunol 1991; 9: 21-4
6. Shahum E, Thérien HM. Liposomal adjuvanticity: effect of encapsulation and surface-linkage on antibody production and proliferative response. Int J Immunopharmacol 1995; 17 (1): 9-20
7. Tan LSK. Liposomes as antigen vehicles to increase immunogenicity: effects of variation of structural characteristics. Ann Acad Med 1991; 20 (1): 78-83
8. Kawamura H, Rosenberg SA, Berzofsky JA. Immunization with antigen and interleukin 2 in vivo overcomes lr gene low responsiveness. J Exp Med 1985 Jul; 162: 381-6
9. Good MF, Pombo D, Lunde MN, et al. Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides: correlation of effect with biologic activity of IL-2. J Immunol 1988 Aug 1; 141 (3): 972-7
10. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection: immunization of guinea pigs with herpes simplex virus subunit vaccines. J Immunol 1988 Jan 1; 140 (1): 294-9
11. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991 Apr; 9 (4): 694-704
12. Anderson PM, Katsanis E, Leonard AS, et al. Increased local antitumor effects of interleukin-2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 1990 Mar 15; 50: 1853-6
13. Utsugi T, Dinney CPN, Killion JJ, et at. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin-2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res 1991; 10 (6): 487-93
14. Loeffler CM, Platt JL, Anderson PM, et al. Anti-tumor effects of IL-2 liposomes and anti-CD3 stimulated T cells against murine MCA-38 hepatic metastases. Cancer Res 1991; 51: 2127-32
15. Konno H, Yamashita A, Tadakuma T, et al. Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2: antitumor effect of IL-2 liposome. Biotherapy 1991; 3: 211-8
16. Konno H, Maruo Y, Matin AF, et al. Effect of liposomal interleukin-2 on ascites-forming rat hepatoma. J Surg Oncol 1992; 51: 33-7
17. Oya M. Antitumor effect of interleukin-2 entrapped in liposomes on murine renal cell carcinoma. Keio J Med 1994 Mar; 43 (1): 37-44
18. Mbawuike IN, Wyde PR, Anderson PM. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990 Aug; 8: 347-52
19. Sencer SF, Rich ML, Katsanis E, et al. Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma. Eur Cytokine Netw 1991; 25: 311-8
20. Bergers JJ, Den Otter W, Dullens HFJ, et al. Interleukin-2 containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines. Pharm Res 1993; 10 (12) 1715-21
21. Ho RJY, Burke RL, Merigan TC. Liposome-formulated interleukin-2 as an adjuvant recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. Vaccine 1992; 10 (4): 209-13
22. Abraham E, Shah S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 1992 Dec; 149 (11): 3719-26
23. Anderson PM, Katsanis E, Sencer SF, et al. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1992; 12: 19-31
24. Anderson PM, Hasz D, Dickrell L, et al. Interleukin-2 in liposomes: increased intravenous potency and less pulmonary toxicity in the rat. Drug Dev Res 1992; 27: 15-31
25. Kedar E, Rutkowski Y, Braun E, et al. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother 1994; 16: 47-59
26. Kedar E, Braun E, Rutkowski Y, et al. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and antitumor activity in mice. J Immunother 1994; 16: 115-24
27. Anderson PM, Hanson DC, Hasz DE, et al. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γ. Cytokine 1994 Jan; 6 (1): 92-101
28. Lachman LB, Shih LCN, Rao XM, et al. Cytokine-containing liposomes as adjuvants for subunit vaccines. In: Powel MF, Newmann MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995: 659-71
29. Eppstein DA, Marsh YV, Van Der Pas M, et al. Biological activity of liposome encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc Natl Acad Sci USA 1985; 82: 3688-92
30. Weiner N, Williama N, Birch G, et al. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother 1989; 33: 1217-21
31. Jolivet M, Sache E, Audibert F. Biological studies of lipophilic MDP-derivatives incorporated in liposomes. Immunol Commun 1981; 10 (6): 511-22
32. Taubman MA, Ebersole JL, Smith DJ, et al. Adjuvants for secretory immune responses. Ann NY Acad Sci 1983; 409: 637-49
33. Fujimaki W, Itoh K, An T, et al. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother 1993; 8 (4): 307-18
34. Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 1993; 14: 286-92
35. Bui T, Dykers T, Hu SL, et al. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J Acquir Immune Defic Syndr 1994; 7: 799-806
36. Bergers JJ, Den Otter W, Dullens HFJ, et al. Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens. Int J Cancer 1994; 56: 721-6
37. Philip R, Brunette E, Kilinski L. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed cationic liposomes. Mol Cell Biol 1994 Apr; 2411-8
38. Vieweg J, Boczkowski D, Roberson KM, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995 Jun 1; 55: 2366-72
39. Mori A, Huang L. Targeted immunoliposomes: potential role in the delivery of cytotoxic drugs. Clin Immunother 1995; 3 (3): 227-40
40. Gilbert BE, Wilson SZ, Garcon NM, et al. Characterization and administration of cyclosporin A liposomes as a small particle aerosol. Transplantation 1993; 56: 974-7
41. Waldrep JC, Scherer PW, Keyhani K, et al. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int J Pharm 1993; 97: 205-12
42. Knight V, Waldrep JC. New approaches in aerosol drug delivery for the treatment of asthma. In: Kay B, editor. Allergy and allergic diseases. Oxford: Blackwell Science, 1997: 726-37
43. Goldbach P, Dumont S, Kessler et al. In situ activation of mouse alveolar macrophages by aerosolized liposomal interferon gamma and muramyl tripeptide. Am J Physiol (Lung Cell Mol Physiol) 1996; 270: L429-34
44. Khanna C, Hasz DE, Klausner JS, et al. Aerosol delivery of interleukin-2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996; 2: 721-34
45. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994; 27 (1): 19-31
46. Clarke CJ, Stokes CR. The intestinal and serum humoral immune response of mice to systemically and orally administered antigens in liposomes. I. The response to liposome-entrapped soluble protein. Vet Immunol Immunopathol 1992; 32: 125-38
47. Clarke CJ, Stokes CR. The intestinal and serum humoral immune response of mice to orally administered antigens in liposomes. II. The response to liposome-entrapped bacterial proteins. Vet Immunol Immunopathol 1992; 32: 139-48
48. Lycke N, Bromander AK, Ekman L, et al. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J Immunol 1989 Jan 1; 142 (1): 20-7
49. Nashar TO, Amin T, Marcello A, et al. Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine 1993; 11 (2): 235-40
50. Frenchiek PJ, Sabara MIJ, Ready KFM, et al. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles. Vaccine 1992; 10 (11): 783-91
51. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343: 322-4
52. Hilbert A, Hudecz F, Mezo G, et al. The influence of branched polypeptide carriers on the immunogenicity of predicted epitopes of HSV-1 glycoprotein D. Scand J Immunol 1994; 40: 609-17
53. Van de Water B, Van Berkel TJC, Kuiper J. Activation of rat kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein. Mol Pharmacol 1994; 45: 971-7
54. Morein B, Sundquist B, Höglund S, et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984 Mar 29; 308: 457-9
55. Morgan AJ, Finerty S, Lovgren K, et al. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulated complexes. J Gen Virol 1988; 69: 2093-6
56. Ahmeida ETSB, Gregoriadis G, Potter CW, et al. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993; 11 (13): 1302-9
57. Golumbek PT, Azhari R, Jaffe EM, et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993 Dec 15; 53: 5841-4
58. Langer R. New methods of drug delivery. Science 1990 Sep 28; 249: 1527-33
59. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable and biocompatible poly (DL-Lactide-co-Glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991 Sept; 59 (9): 2978-86
60. Degling L, Sjarnkvist P, Sjoholm I. Interferon gamma in starch microparticles: nitric oxide generating activity in vitro and antileishmanial effect in mice. Pharm Res 1993; 10: 783-90
61. Kalish ML, Check IJ, Hunter RL. Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG). I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on Isotype selection. J Immunol 1990 May 15; 146 (10): 3583-90
62. Hunter RL, McNicholl J, Lal AA. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res Hum Retrovir 1994; 10 Suppl. 2: S95-S98
63. Sorenson MA, Zebede M, Anderson PM, et al. Interleukin-2 lipid microspheres. I. Development and evaluation of the colloidal drug carrier. Drug Deliv 1995; 2: 198-206
64. Sorenson MA, Zebede M, Anderson PM, et al. Interleukin-2 lipid microspheres. II. In vitro and in vivo assessment of a colloidal drug carrier containing interleukin-2. Drug Deliv 1995; 2: 207-14
65. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA 1993 Feb; 90: 1513-7
66. Puolakkainen PA, Ranchalis JE, Gombotz WR, et al. Novel delivery system for inducing quiescence in intestinal stem cells in rats by transforming growth factor β1. Gastroenterology 1994; 107: 1319-26
67. Sullivan LM, Bober LA, Grace MJ, et al. Potential interaction of interleukin-4 with endogenous cytokines in vivo. Pathobiology 1994; 62: 59-72
68. Al-Hendy, A, Hortelano G, Tannenbaum GS, et al. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts: an alternate approach to somatic gene therapy. Hum Gene Ther 1995; 6: 165-75
69. Nakayama K, Kelly SM, Curtiss R. Construction of an ASD+ expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Biotechnology 1988; 6: 693-7
70. Saltzman DA, Heise CP, Katsanis E, et al. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. Cancer Biother 1996. In press
71. Antimisiaris SG, Jayasekera P, Gregoriadis G. Liposomes as vaccine carriers: incorporation of soluble and particulate antigens in giant vesicles. J Immunol Methods 1993; 166: 271-80
72. Ramshaw IA, Andrew ME, Phillips SM, et al. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987; 329: 547-50
73. Olmssted RA, Buller RML, Murphy BR, et al. Evaluation in nonhuman primates of the safety, immunogenicity, and efficacy of recombinant vaccinia virus. In: Ginsberg H, Brown F, Lerner RA, et al., editors. Vaccines 88: new chemical and genetic approaches to vaccines. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory, 1988: 205-10
74. Flexner C, Moss B, London WT, et al. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 1990; 8: 17-21
75. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989 May 5; 57: 503-12
76. Li W, Diamantstein T, Blankenstein T. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol 1990; 27 (12): 1331-37
77. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991 Nov; 254: 713-6
78. Fearon E, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990 Feb 9; 60: 397-403
79. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990 Oct; 172: 1217-24
80. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990 Dec 15; 50: 7820-5
81. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989 Dec; 86: 9456-60
82. Asher AL, Mulé JJ, Kashid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol 1991 May 1; 146 (9): 3227-34
83. Blankenstein T, Qin Z, Überla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor-α gene transfer. J Exp Med 1991 May; 173: 1047-52
84. Teng MN, Park BH, Koeppen HKW, et al. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia of T-cell immunity. Proc Natl Acad Sci USA 1991 May; 88: 3535-9
85. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991 Apr; 173: 889-97
86. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991 Jun; 11 (6): 3125-31
87. Hock H, Dorsch M, Diamantstein T, et al. Interleukin-7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1992 Dec; 174: 1291-8
88. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin-7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992 May; 89: 3850-4
89. Porgador A, Tzhoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic conpetence against parental metastatic cells. Cancer Res 1992; 52: 3679-86
90. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43